Latest News

Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...

Cyclophosphamide, doxorubicin, vincristine, and prednisone with romidepsin did not yield improved efficacy for patients with previously untreated peripheral T-cell lymphoma compared to CHOP alone, according to the phase 3 Ro-CHOP trial.

Imatinib prophylaxis demonstrated outcomes comparable to dasatinib among patients with Philadelphia-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation at first complete remission, according to a retrospective...

According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...

Combining a hypomethylating agent, venetoclax, and gilteritinib treatment yielded beneficial outcomes and can be used as a bridge to allogeneic stem cell transplantation for patients with R/R FLT3-mutated acute myeloid leukemia.

The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.

A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.

According to a retrospective study, patients who experienced a dose reduction while on cabozantinib for metastatic renal cell carcinoma had improved overall survival and time to treatment failure.

The FDA has approved amivantamab for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 mutations, as detected by an FDA-approved test.

On March 7, 2024, the FDA approved nivolumab plus gemcitabine and cisplatin for patients with unresectable or metastatic urothelial carcinoma in the first-line setting.